• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ENDOLOGIX AFX; BIFURCATED STENT GRAFT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ENDOLOGIX AFX; BIFURCATED STENT GRAFT Back to Search Results
Model Number BA28-100/I20-40
Device Problems Collapse (1099); Material Puncture/Hole (1504); Insufficient Information (3190)
Patient Problems Aneurysm (1708); Failure of Implant (1924); Pain (1994)
Event Date 10/11/2021
Event Type  Injury  
Manufacturer Narrative
The devices involved in this event will not be returned for evaluation and remain implanted in the patient.Patient medical records and imaging studies will be requested for further evaluation by a clinical specialist.If additional information pertinent to the incident is obtained, a follow-up report will be submitted.Device iteration is afx with duraply.
 
Event Description
The patient was initially treated for an abdominal aortic aneurysm (aaa) with implant of an afx bifurcated stent graft and an afx vela suprarenal.Approximately six (6) years and five (5) months post initial procedure, the patient presented emergently with right flank pain.Aneurysm enlargement and a possible type iiia endoleak were identified.Patient is currently in the hospital for a gastrointestinal (gi) bleed.After the gi bleed has been fixed a reintervention will be performed to re-line aneurysm enlargement and a possible type iiia endoleak.
 
Event Description
The patient was initially treated for an abdominal aortic aneurysm (aaa) with implant of an afx bifurcated stent graft and an afx vela suprarenal.Approximately six (6) years and five (5) months post initial procedure, the patient presented emergently with right flank pain.Aneurysm enlargement and a possible type iiia endoleak were identified.Patient is currently in the hospital for a gastrointestinal (gi) bleed.After the gi bleed has been fixed a reintervention will be performed to re-line aneurysm enlargement and a possible type iiia endoleak.Subsequent to the initial report, additional information was provided reporting that the patient underwent coiling to treat the type ii endoleak.Additionally, clinical assessment determined that there was evidence to reasonably suggest buckling of the distal bifurcated stent graft occurred that was not included in the event as reported.The buckling was discovered during review of the 78 month post-implant ct scan.
 
Manufacturer Narrative
The reported adverse event/incident was investigated in alignment with endologix operating procedures and work instructions.Where possible, it is endologix practice to make at least three good faith efforts to retrieve a reported adverse event/incident related device as well as medical records and medical imaging.An evaluation of the manufacturing record was completed.A review of the part number/lot number combination needed for device identification shows the device to have been properly manufactured and released in accordance with the device master record.An evaluation of the device could not be completed.The device was not returned to endologix for evaluation because it remains implanted.A clinical evaluation of the adverse event/incident was completed.An examination of medical records and/or medical imaging received by endologix shows the type iiia endoleak adverse event/incident is refuted, rather there was a type iiib endoleak of the distal bifurcated stent graft.The sac growth of 34.5mm adverse event/incident is confirmed.The type ii endoleak of the internal mesenteric and lumbar artery adverse event/incident is confirmed.This is moderately consistent with the reported adverse event/incident.The clinical evaluation also shows reasonable evidence to suggest buckling of the distal bifurcated stent graft occurred that was not included in the event as reported.These findings were discovered during an examination of the 78-month post implant ct scan.The most likely causation for type iiib endoleak is the distal buckling of the bifurcated stent graft in a 40-degree angulation.The most likely causation for the type ii endoleak is anatomy related.The final patient status was reported as being discharged on the fifth post-operative day following a secondary endovascular procedure (ima coiling).No additional investigation of this reported adverse event/incident is planned.However, should additional information relevant to the investigation outcome become available, a follow-up report will be submitted.Endologix will continue to monitor this and similar adverse events/incidents.Device iteration is afx with duraply.B2: outcomes attributed to adverse event ¿ updated b5: describe event or problem - updated g3: awareness date ¿ updated h6: medical device problem codes ¿ remove 3190 h6: investigation finding codes: remove code 3233 h6: investigation conclusion codes: remove code 11.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AFX
Type of Device
BIFURCATED STENT GRAFT
Manufacturer (Section D)
ENDOLOGIX
2 musick
irvine CA 92618
Manufacturer (Section G)
ENDOLOGIX
2 musick
,
irvine CA 92618
Manufacturer Contact
gary kirchgater
2 musick
,
irvine, CA 92618
8009832284
MDR Report Key12668840
MDR Text Key278422945
Report Number2031527-2021-00441
Device Sequence Number1
Product Code MIH
UDI-Device Identifier00818009014207
UDI-Public(01)00818009014207(17)171103
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P040002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Health Professional,Company Representative
Reporter Occupation Physician
Remedial Action Recall
Type of Report Initial,Followup
Report Date 10/11/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date11/03/2017
Device Model NumberBA28-100/I20-40
Device Lot Number1284146-014
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 10/11/2021
Initial Date FDA Received10/20/2021
Supplement Dates Manufacturer Received12/13/2021
Supplement Dates FDA Received12/28/2021
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured11/18/2014
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Removal/Correction NumberZ-0006-2019
Patient Sequence Number1
Treatment
AFX VELA SUPRARENAL (LN 1252463005)
Patient Outcome(s) Other; Required Intervention;
Patient Age90 YR
Patient SexMale
-
-